Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine
family and is implicated in immune responses to infectious pathogens and in the …

Obesity is a growing epidemic worldwide, and it is also considered a major environmental
factor contributing to the pathogenesis of inflammatory skin diseases, including psoriasis …

Background Drug survival analysis of biologic agents in psoriasis is of extreme importance,
as it allows not only the evaluation of objective clinical outcomes (such as effectiveness and …

Background The efficacy of biological therapies used for the treatment of chronic plaque
psoriasis can be influenced by numerous variables including body mass index (BMI) …

Real‐world evidence (RWE) meta‐analyses provide valuable insights from patients in
routine clinical practice. Secukinumab, the first fully human monoclonal antibody that …

Objectives To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA)
on secukinumab followed for 24 months:(1) the long-term effectiveness and safety of …

Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases,
each commonly manifesting as a spectrum of symptoms, complications, and comorbidities …

Abstract Objective: This European, multicentric, retrospective study aimed to collect data on
secukinumab effectiveness in a real-world setting. Research design and methods: All …

Psoriasis is an inflammatory skin disease with a background of polygenic inheritance. Both
environmental and genetic factors are involved in the etiology of the disease. In the last two …

Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …